This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Dengue, Dengue Hemorrhagic Fever or Yellow Fever
and you are
between 12 and 13
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration. Primary Objective: - To demonstrate the non-inferiority of the immune response against Yellow Fever (YF) in flavivirus (FV) non-immune subjects at baseline receiving one dose of Stamaril vaccine administered concomitantly with the first dose of CYD dengue vaccine compared to participants receiving one dose of Stamaril vaccine concomitantly with placebo. Secondary Objectives: - To assess the non-inferiority of YF immune response 28 days post-Stamaril vaccination based on seroconversion rates regardless of the FV status of participants at baseline. - To describe the YF immune response 28 days post-Stamaril vaccination in both groups. - To describe the antibody (Ab) response to each dengue virus serotype 28 days post CYD dengue vaccine (Visit [V] 05 and V07), following CYD dengue vaccine Dose 1 and Dose 2 from Group 2 versus following CYD dengue vaccine Dose 2 and Dose 3 for Group 1 (effect of YF vaccination). - To describe the safety of Stamaril vaccine administered concomitantly with the first dose of CYD dengue vaccine, or Stamaril administered concomitantly with placebo. - To describe the safety of CYD dengue vaccine after the first dose of CYD dengue vaccine administered concomitantly with Stamaril vaccine or CYD vaccine administered alone. - To describe the safety of the CYD dengue vaccine in all participants after each dose.

Provided treatments

  • Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus
  • Biological: Yellow fever vaccine
  • Biological: Measles, mumps, and rubella (MMR) vaccine
  • Biological: Pneumococcal Conjugated Vaccine
  • Biological: Hepatitis A Pediatric Vaccine
  • Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
  • Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus
  • Biological: Yellow Fever Vaccine
  • Biological: Placebo (NaCl)
  • Biological: Measles, mumps, and rubella vaccine
  • Biological: Pneumococcal Conjugated Vaccine
  • Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
  • Biological: Hepatitis A Pediatric Vaccine

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01436396. The sponsor of the trial is Sanofi Pasteur, a Sanofi Company and it is looking for 792 volunteers for the current phase.
Official trial title:
Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru